Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Long-acting exenatide data

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Lilly and Amylin announce data Aug. 22 from a 45-patient Phase II study of a long-acting release (LAR) formulation of the incretin mimetic Byetta (exenatide) in type 2 diabetes using Alkermes' Medisorb injectable extended-release delivery technology. Patients in the 15-week study were randomized to one of two once-weekly doses of exenatide LAR or placebo. HbA1C "improved approximately 2% for subjects receiving the high dose of exenatide LAR compared to placebo," Amylin says; baseline A1C in the study was 8.5%. Fasting blood glucose concentrations decreased approximately 50 mg/dL in the high dose group vs. placebo, the firm reports. FDA approved immediate-release Byetta on April 28 for twice-daily dosing (1Pharmaceutical Approvals Monthly May 2005, p. 20)...

You may also be interested in...

Approvals In Brief

Lilly/Amylin Byetta clears FDA as first incretin mimetic; GSK readies Boostrix launch following May 3 BLA approval. GlaxoSmithKline’s dopamine agonist Requip (ropinirole) is approved May 4 as the first treatment for restless legs syndrome. More FDA approvals in brief

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts